Jay Moorin
CIK 1033508 · last filed 2017-01-06
Jay Moorin is a corporate insider who has filed 27 SEC Form 4 insider transactions across 6 companies since 2007. The most recent filing shows the insider sold $27.7M of EGRX on Jan 6, 2017. Across all open-market trades the lifetime net is −$55.1M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.0M across reported positions. 85 SEC filings were submitted jointly with ALAIN SCHREIBER.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$1.00M
6
27
-$55.10M
Filer Profile
2430 VANDERBILT BEACH ROAD, #108 - 190
NAPLES, FL 34109
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| EAGLE PHARMACEUTICALS, INC. (EGRX) Delisted | Director | 26,174 | $2.14 | $56.0K | -$70.97M | 10 | 2017-01-06 |
| AGILE THERAPEUTICS INC (AGRX) Delisted | 10%+ Owner | 2,531 | $1.51 | $3.8K | $15.00M | 1 | 2016-01-29 |
| NVD | 10%+ Owner | 250,703 | $3.99 | $1.00M | $0 | 1 | 2009-05-05 |
| AVANIR PHARMACEUTICALS, INC. (AVNR) Delisted | 10%+ Owner | 9,798,866 | — | — | $2.51M | 7 | 2008-10-24 |
| CADENCE PHARMACEUTICALS INC (CADX) Delisted | 10%+ Owner | 2,928,831 | — | — | -$1.63M | 2 | 2007-09-12 |
| Paratek Pharmaceuticals, Inc. (NOVC) Delisted | Director | 1,855,275 | — | — | $0 | 1 | 2007-01-19 |
Recent Filings
27 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-01-06 | EAGLE PHARMACEUTICALS, INC. (EGRX) Delisted | Sell (S) | −325,570 | -$27.73M | EDGAR |
| 2016-11-14 | EAGLE PHARMACEUTICALS, INC. (EGRX) Delisted | Sell (S) | −172,430 | -$14.68M | EDGAR |
| 2016-10-04 | EAGLE PHARMACEUTICALS, INC. (EGRX) Delisted | Sell (S) | −110,500 | -$7.74M | EDGAR |
| 2016-09-08 | EAGLE PHARMACEUTICALS, INC. (EGRX) Delisted | Sell (S) | −354,625 | -$22.16M | EDGAR |
| 2016-05-16 | EAGLE PHARMACEUTICALS, INC. (EGRX) Delisted | Sell (S) | −89,900 | -$3.66M | EDGAR |
| 2016-01-29 | AGILE THERAPEUTICS INC (AGRX) Delisted | Buy (P) | +2,362,200 | $15.00M | EDGAR |
| 2016-01-14 | — | Grant (A) | — | $0 | |
| 2016-01-05 | EAGLE PHARMACEUTICALS, INC. (EGRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-07-02 | EAGLE PHARMACEUTICALS, INC. (EGRX) Delisted | Other (J) | −14,850 | $0 | EDGAR |
| 2015-04-22 | EAGLE PHARMACEUTICALS, INC. (EGRX) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.